@article{ref1,
title="Clonazepam improves dopamine supersensitivity in a schizophrenia patient: a case report",
journal="Therapeutic advances in psychopharmacology",
year="2017",
author="Fukai, M. and Hirosawa, T. and Takahashi, T. and Kaneda, R. and Kikuchi, M. and Minabe, Y.",
volume="7",
number="3",
pages="113-117",
abstract="Dopamine supersensitivity is an important consideration for assessing treatment-resistant schizophrenia. The emergence of dopamine supersensitivity might be related to upregulation of dopamine D2 receptor, which engenders tolerance to antipsychotics, rebound psychosis, and tardive dyskinesia (TD). A 24-year-old man with a history of treatment-resistant schizophrenia was hospitalized for treatment of bone fracture sustained during a suicide attempt. After the operation, his clinical symptoms implied malignant catatonia. The patient discontinued antipsychotics without rebound psychosis under clonazepam treatment. His psychotic symptoms were controlled further with 24 mg/day aripiprazole without relapse or worsening. Clonazepam might be an effective option for the management of dopamine supersensitivity psychosis (DSP). © 2016, © The Author(s), 2016.<p /><p>Language: en</p>",
language="en",
issn="2045-1253",
doi="10.1177/2045125316681750",
url="http://dx.doi.org/10.1177/2045125316681750"
}